Veranova is a global leader in the development and manufacturing of complex and specialty APIs, with decades of experience in ADC linker-payloads, oligonucleotides, highly potent APIs (HPAPIs), and controlled substances.
Managing Complexity with Confidence: Veranova Supports Your New Modalities, HPAPIs, and Other Specialized APIs
Veranova is a global leader in the development and manufacturing of complex active pharmaceutical ingredients (APIs), offering specialized expertise in antibody–drug conjugate (ADC) linker-payloads, oligonucleotides, highly potent APIs (HPAPIs), controlled substances, and solid form science:
- Veranova brings over 20 years of experience developing and manufacturing ADC linker-payloads, with deep knowledge of multiple ADC linker–payload systems and comprehensive services to support your project from early development through large-scale commercial manufacturing.
- Veranova is a leading manufacturer of controlled substances, HPAPIs, and generic APIs—with more than 50 years of experience and 200+ active drug master files (DMFs).
- Veranova’s Pharmorphix® team brings deep expertise in solid form science and particle engineering with more than 2,500 completed customer projects.
As modalities such as ADC linker-payloads, peptides, oligonucleotides, and other APIs become more sophisticated, complexity can take different forms depending on the molecule. It can involve structurally challenging chemistry, controlled substances, high-potency compounds that demand specialized containment, or purification and analytical methods that go beyond standard approaches. By evaluating each molecule’s synthetic route, potency, development stage, and regulatory requirements, Veranova anticipates and manages complexity from day one.
Learn More About Veranova at CPHI Milan
Come see Veranova at booth 10K33 at CPHI Milan! The team is ready to answer your questions about how Veranova’s experts can support the development and manufacturing of your complex molecules.
Complexity at Scale
Veranova continues to expand its capacity for complex new modalities at its Devens, Massachusetts site, where a $50 million investment is underway to add process development and cGMP manufacturing space for HPAPIs and ADC linker-payloads.
You can learn more about Veranova’s capabilities for new and complex modalities—ADCs, proteolysis targeting chimeras (PROTACs), oligonucleotides, polyethylene glycol (PEG) derivatives, and HPAPIs at www.veranova.com.
